Acorda Therapeutics - ACOR Stock Forecast, Price & News

Acorda Therapeutics' stock was trading at $2.39 on January 1st, 2022. Since then, ACOR stock has decreased by 74.5% and is now trading at $0.6096.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our ACOR earnings forecast.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) posted its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($1.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.56) by $0.13. The biopharmaceutical company had revenue of $31.46 million for the quarter, compared to analysts' expectations of $30.57 million. Acorda Therapeutics had a negative trailing twelve-month return on equity of 96.44% and a negative net margin of 85.97%.

Shares of Acorda Therapeutics reverse split on the morning of Monday, January 4th 2021. The 1-6 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 31st 2020. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Acorda Therapeutics updated its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $116.00 million-$119.70 million, compared to the consensus revenue estimate of $120.51 million.

39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Acorda Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.52%). Insiders that own company stock include Jane Wasman and Ron Cohen.
View institutional ownership trends.

Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACOR stock can currently be purchased for approximately $0.61.

Acorda Therapeutics (NASDAQ:ACOR) has a market capitalization of $14.80 million and generates $129.07 million in revenue each year. The biopharmaceutical company earns $-103,950,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis.

The company employs 118 workers across the globe.

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The official website for the company is www.acorda.com. The biopharmaceutical company can be reached via phone at (914) 347-4300 or via fax at 914-347-4560.